Sarepta Therapeutics/$SRPT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Sarepta Therapeutics
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
Ticker
$SRPT
Sector
Primary listing
Employees
1,372
Headquarters
Website
SRPT Metrics
BasicAdvanced
$1.7B
-
-$0.60
0.45
-
Price and volume
Market cap
$1.7B
Beta
0.45
52-week high
$133.15
52-week low
$10.42
Average daily volume
9M
Financial strength
Current ratio
2.888
Quick ratio
1.443
Long term debt to equity
99.742
Total debt to equity
100.509
Interest coverage (TTM)
-0.03%
Profitability
EBITDA (TTM)
40.147
Gross margin (TTM)
22.77%
Net profit margin (TTM)
-2.34%
Operating margin (TTM)
-0.04%
Effective tax rate (TTM)
-140.17%
Revenue per employee (TTM)
$1,810,000
Management effectiveness
Return on assets (TTM)
-0.02%
Return on equity (TTM)
-4.76%
Valuation
Price to revenue (TTM)
0.681
Price to book
1.26
Price to tangible book (TTM)
1.26
Price to free cash flow (TTM)
-3.724
Free cash flow yield (TTM)
-26.85%
Free cash flow per share (TTM)
-4.691
Growth
Revenue change (TTM)
64.89%
Earnings per share change (TTM)
-222.03%
3-year revenue growth (CAGR)
43.76%
10-year revenue growth (CAGR)
116.72%
3-year earnings per share growth (CAGR)
-53.48%
10-year earnings per share growth (CAGR)
-17.87%
What the Analysts think about SRPT
Analyst ratings (Buy, Hold, Sell) for Sarepta Therapeutics stock.
Bulls say / Bears say
Sarepta reported positive expression and functional data from its SRP-9003 gene therapy trial in limb-girdle muscular dystrophy Type 2E, with a 73% mean signal intensity and an 89% reduction in creatine kinase at the high dose, highlighting robust early efficacy (Reuters).
An FDA advisory panel backed accelerated approval for Sarepta’s SRP-9001 gene therapy for Duchenne muscular dystrophy, voting 8-6 that the company provided sufficient data to support the application, significantly increasing the likelihood of a May 2025 approval decision (Reuters).
The collaboration with Codiak Biosciences to develop exosome-based therapeutics for rare diseases could deliver up to $72.5 million in upfront and near-term licensing payments plus research funding, bolstering the pipeline and improving near-term cash flow (Reuters).
Commercial shipments of Elevidys were partially suspended following the deaths of two teenage patients, undermining physician and patient confidence and posing a significant reputational risk to Sarepta’s largest revenue generator (Reuters).
The company announced cost‐cutting measures, including halting a gene therapy study and implementing layoffs after a trial participant’s death, reflecting operational and financial strain on Sarepta’s resources (Reuters).
Sarepta’s share price has plunged nearly 90% year-to-date amid these safety and operational challenges, indicating sharply reduced investor confidence in the company’s near-term prospects (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2025.
SRPT Financial Performance
Revenues and expenses
SRPT Earnings Performance
Company profitability
SRPT News
AllArticlesVideos
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic Year
Business Wire2 weeks ago
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
Business Wire3 weeks ago
SRPT Deadline: Rosen Law Firm Urges Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
Business Wire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Sarepta Therapeutics stock?
Sarepta Therapeutics (SRPT) has a market cap of $1.7B as of September 16, 2025.
What is the P/E ratio for Sarepta Therapeutics stock?
The price to earnings (P/E) ratio for Sarepta Therapeutics (SRPT) stock is 0 as of September 16, 2025.
Does Sarepta Therapeutics stock pay dividends?
No, Sarepta Therapeutics (SRPT) stock does not pay dividends to its shareholders as of September 16, 2025.
When is the next Sarepta Therapeutics dividend payment date?
Sarepta Therapeutics (SRPT) stock does not pay dividends to its shareholders.
What is the beta indicator for Sarepta Therapeutics?
Sarepta Therapeutics (SRPT) has a beta rating of 0.45. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.